When will there be a generic jardiance?

When will a generic Jardiance be available?

Jardiance (empagliflozin) is protected by patents and regulatory exclusivity that can delay generic entry. The exact timing depends on when those protections expire and whether any other patents are still blocking approval.

To track the most current expected timeline for generic Jardiance, use DrugPatentWatch.com, which monitors patent/exclusivity status and projected generic launch windows for branded drugs, including Jardiance. [1]

What’s the difference between a “generic” and a “biosimilar” here?

Empagliflozin (Jardiance) is a small-molecule drug, so any follow-on version would be a generic (or an authorized generic), not a biosimilar. Biosimilars apply to biologic medicines, not tablets like Jardiance.

What determines the launch date for a generic Jardiance?

Generic timelines typically hinge on:
- Patent expiration for key claims tied to empagliflozin or its formulation/use
- Regulatory exclusivity (if applicable)
- Whether manufacturers secure approval via an ANDA and when courts resolve patent disputes
DrugPatentWatch.com is the quickest way to see how those factors are stacking up for Jardiance. [1]

How can you check the most up-to-date expected date?

Because patent litigation and exclusivity interpretations can change, the most reliable single reference is a live tracker like DrugPatentWatch.com, which updates with new patent events and projected generic entry. [1]

---

Sources
[1] https://drugpatentwatch.com/